Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

Cristiane Decat Bergerot,Sun Young Rha,Sumanta K. Pal,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Jae-Lyun Lee,Kaisa Sunela,Tudor Ciuleanu,Daniel Yick Chin Heng,Hilary Glen,Jinyi Wang,Lee Bennett,Janice Pan,Karen OHara,Javier Puente

Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

2021

Cristiane Decat Bergerot
Sun Young Rha
Sumanta K. Pal
Piotr Koralewski
Daniil Stroyakovskiy
Boris Alekseev
Francis Parnis
Daniel Castellano
Jae-Lyun Lee
Kaisa Sunela
Tudor Ciuleanu
Daniel Yick Chin Heng
Hilary Glen
Jinyi Wang
Lee Bennett
Janice Pan
Karen OHara
Javier Puente

314Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer, constituting 80% to 85% of primary renal neoplasms. Preserving health-related quality of life (HRQOL) is an impor...

Keywords:

Quality of life
Kidney cancer
Oncology
Lenvatinib
Renal neoplasm
health related quality of life
Everolimus
Renal cell carcinoma
Internal medicine
Medicine
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations